Sodium Chloride 0.9% ( DrugBank: Sodium chloride, Chloride )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	3
227	オスラー病	1

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

---

臨床試験数 : 175 /  薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-002511-34-GB (EUCTR)	01/04/2019	08/11/2019	Initial treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - combined immunoglobulin and steroid treatment versus immunoglobulin treatment alone.	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP - OPTIC Trial	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) MedDRA version: 21.1;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: methylprednisolone Product Name: methylprednisolone Trade Name: sodium chloride 0.9% Product Name: sodium chloride 0.9%	Academic Medical Centre, Amsterdam, NL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands;United Kingdom
2	EUCTR2017-002511-34-NL (EUCTR)	26/09/2018	17/04/2018	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial)	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial) - OPTIC trial	Chronic inflammatory demyelinating polyneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Methylprednisolone (Solu-Medrol) Product Name: Methylprednisolon (Solu-Medrol) Trade Name: Sodium Chloride 0.9% Product Name: Sodium Chloride 0.9% Product Code: RVG 56083	Academisch Medisch Centrum	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands
3	EUCTR2013-005363-52-NL (EUCTR)	10/09/2014	27/03/2014	Intravenous immunoglobulin overtreatment in CIDP	Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy (CIDP)	Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sodium Chloride 0.9% Product Name: Sodium Chloride 0.9% Product Code: RVG 51680	Department of Neurology, Academic Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

227. オスラー病

---

臨床試験数 : 56 /  薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03227263 (ClinicalTrials.gov)	September 28, 2017	21/7/2017	BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).	BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study	Rendu Osler Disease;Telangiectasia, Hereditary Hemorrhagic	Drug: Bevacizumab;Drug: sodium chloride 0.9%	Hospices Civils de Lyon	NULL	Completed	18 Years	N/A	All	24	Phase 3	France